UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Unipolar major depression in adults: Augmentation of antidepressants with stimulants and stimulant-like drugs

Author
Andrew Nierenberg, MD
Section Editor
Peter P Roy-Byrne, MD
Deputy Editor
David Solomon, MD

INTRODUCTION

Stimulants (eg, methylphenidate) are primarily used to treat attention deficit hyperactivity disorder (ADHD), and stimulant-like drugs such as modafinil are used for narcolepsy, obstructive sleep apnea, and sleep shift work disorder [1]. However, stimulants have also been used for decades as add-on treatment in patients with unipolar major depression who have not responded adequately to antidepressant monotherapy. In a retrospective study of patients with unipolar major depression who were treated with an antidepressant and then received augmentation therapy (n >3200), stimulants were used in 5 percent of the patients [2].

This topic reviews the efficacy of stimulants and stimulant-like drugs for augmentation of antidepressants in treatment-resistant, unipolar major depression. Choosing a drug regimen for treatment-resistant depression is discussed separately. (See "Unipolar depression in adults: Treatment of resistant depression".)  

RATIONALE

Adjunctive therapy for unipolar major depression is often required because initial treatment with a single antidepressant leads to remission in only 30 to 50 percent of patients [3-5]. Options for add-on treatment include second-generation antipsychotics, lithium, triiodothyronine, a second antidepressant, and psychotherapy (eg, cognitive-behavioral therapy). It is also thought that stimulants and stimulant-like drugs may be useful for patients with treatment-resistant depression because these drugs may ameliorate symptoms such as anergia, fatigue, hypersomnia, and impaired concentration, which are often initial or residual symptoms of major depression as well as side effects of some antidepressants [6,7].

In addition, it is biologically plausible that stimulants may be of value for treating depression when combined with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). The pathophysiology of major depression may involve insufficient monoaminergic neurotransmission, and SSRIs initially increase serotonergic activity and SNRIs increase serotonergic and noradrenergic activity. However, major depression may also be associated with diminished dopaminergic transmission, and stimulants, modafinil, and pramipexole increase dopaminergic activity [8-10].

INDICATIONS

Stimulant-like drugs (eg, modafinil and pramipexole) are indicated for the general population of patients with treatment-resistant unipolar major depression, and stimulants (eg, methylphenidate) are indicated for late-life, treatment-resistant depression. The use of stimulants and stimulant-like drugs is consistent with multiple treatment guidelines [11-13]. Based upon our clinical experience, we are more inclined to use stimulants and stimulant-like drugs for patients who lack energy, drive, motivation, interest, optimism, pleasure, and the ability to initiate activities [14].

          

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Mon Jul 13 00:00:00 GMT+00:00 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Corp SA, Gitlin MJ, Altshuler LL. A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder. J Clin Psychiatry 2014; 75:1010.
  2. Gersing KR, Sheehan JJ, Burchett B, et al. Use of augmentation agents for treating depression: analysis of a psychiatric electronic medical record data set. Psychiatr Serv 2014; 65:1062.
  3. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163:28.
  4. Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005; 66:974.
  5. Thase ME, Nierenberg AA, Vrijland P, et al. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol 2010; 25:189.
  6. Goss AJ, Kaser M, Costafreda SG, et al. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry 2013; 74:1101.
  7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.
  8. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007; 64:327.
  9. Papakostas GI. Dopaminergic-based pharmacotherapies for depression. Eur Neuropsychopharmacol 2006; 16:391.
  10. Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008; 33:1477.
  11. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third edition. Am J Psychiatry 2010; 167 (supplement):1.
  12. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition, 2010. http://www.psychiatry.org/practice/clinical-practice-guidelines (Accessed on October 04, 2014).
  13. Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009; 117 Suppl 1:S26.
  14. Orr K, Taylor D. Psychostimulants in the treatment of depression : a review of the evidence. CNS Drugs 2007; 21:239.
  15. Ravindran AV, Kennedy SH, O'Donovan MC, et al. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2008; 69:87.
  16. Patkar AA, Masand PS, Pae CU, et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol 2006; 26:653.
  17. Trivedi MH, Cutler AJ, Richards C, et al. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram. J Clin Psychiatry 2013; 74:802.
  18. Candy M, Jones L, Williams R, et al. Psychostimulants for depression. Cochrane Database Syst Rev 2008; :CD006722.
  19. Reimherr FW, Marchant BK, Strong RE, et al. Emotional dysregulation in adult ADHD and response to atomoxetine. Biol Psychiatry 2005; 58:125.
  20. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006; 163:716.
  21. Kessler RC, Adler LA, Barkley R, et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biol Psychiatry 2005; 57:1442.
  22. Hardy SE. Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults. Am J Geriatr Pharmacother 2009; 7:34.
  23. Lavretsky H, Park S, Siddarth P, et al. Methylphenidate-enhanced antidepressant response to citalopram in the elderly: a double-blind, placebo-controlled pilot trial. Am J Geriatr Psychiatry 2006; 14:181.
  24. Lavretsky H, Reinlieb M, St Cyr N, et al. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2015; 172:561.
  25. Wallace AE, Kofoed LL, West AN. Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients. Am J Psychiatry 1995; 152:929.
  26. Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 2005; 66:85.
  27. Thase ME, Fava M, DeBattista C, et al. Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS Spectr 2006; 11:93.
  28. Cusin C, Iovieno N, Iosifescu DV, et al. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. J Clin Psychiatry 2013; 74:e636.
  29. Franco-Chaves JA, Mateus CF, Luckenbaugh DA, et al. Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: a double-blind, randomized pilot study. J Affect Disord 2013; 149:319.
  30. Corrigan MH, Denahan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000; 11:58.
  31. Michelson D, Adler LA, Amsterdam JD, et al. Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68:582.
  32. Cassano P, Lattanzi L, Fava M, et al. Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry 2005; 50:357.
  33. Wada T, Kanno M, Aoshima T, Otani K. Dose-dependent augmentation effect of bromocriptine in a case with refractory depression. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25:457.
  34. Inoue T, Tsuchiya K, Miura J, et al. Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. Biol Psychiatry 1996; 40:151.
  35. McGrath PJ, Quitkin FM, Klein DF. Bromocriptine treatment of relapses seen during selective serotonin re-uptake inhibitor treatment of depression. J Clin Psychopharmacol 1995; 15:289.
  36. Bouras N, Bridges PK. Bromocriptine in depression. Curr Med Res Opin 1982; 8:150.
  37. Goforth H. Amantadine in catatonia due to major depressive disorder in a medically ill patient. J Neuropsychiatry Clin Neurosci 2007; 19:480.
  38. Quarantini LC, Miranda-Scippa A, Schinoni MI, et al. Effect of amantadine on depressive symptoms in chronic hepatitis C patients treated with pegylated interferon: a randomized, controlled pilot study. Clin Neuropharmacol 2006; 29:138.
  39. Izumi T, Inoue T, Kitagawa N, et al. Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression. J Affect Disord 2000; 61:127.